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Context: The sterol regulatory element-binding protein-1c (SREBP-1c) is a transcription factor involved in the regulation of lipid
and glucose metabolism and has been implicated in the pathophysiology of type 2 diabetes mellitus (T2DM).
Objective: We aimed to confirm associations of the SREBF-1 gene with T2DM in an Austrian population and to study possible
associations with diabetes-related quantitative traits.
Design, settings and participants: We genotyped a diabetic cohort (n¼446) along with a control group (n¼ 1524) for a
common C/G variation that is located in exon 18c (rs2297508) and has been associated with obesity and T2DM in French
populations.
Main outcome measures: Body mass index (BMI), indices of insulin sensitivity and b-cell function, plasma adiponectin, T2DM
and single-nucleotide polymorphism rs2297508.
Results: Genotype distributions associated with rs2297508 differed by T2DM status (P¼0.0045), but not by BMI. The variant G
allele was associated with a modest, but significant, increase in the prevalence of T2DM after adjustment for age, sex and BMI
(G/G: odds ratios (OR) (95% confidence intervals)¼1.45 (0.99–2.11) and G/C: OR¼1.37 (1.04–1.81)). In a cross-sectional
population of non-diabetic subjects, associations of rs2297508 genotypes with plasma adiponectin levels adjusted for age, sex
and BMI (P¼0.0017) were observed in that the risk G/G genotype displayed the lowest adiponectin levels.
Conclusions: We observed associations of rs2297508 with T2DM prevalence and plasma adiponectin. SREBP-1c has been
implicated in the regulation of adiponectin gene expression. Our results therefore raise the possibility that sequence variations at
the SREBF-1 gene locus might contribute to T2DM risk, at least in part, by altering circulating adiponectin levels.
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Introduction
The incidence of non-insulin-dependent type 2 diabetes
mellitus (T2DM) is increasing world wide at an alarming rate
in progressively younger populations. Pathophysiologically
characterized by insulin resistance, pancreatic b-cell dysfunc-
tion and enhanced hepatic gluconeogenesis, the exact
etiology of type 2 diabetes is not known, but obesity and
alterations in genetic programs that control glucose and
fatty-acid metabolism are key contributing factors.1
Sterol regulatory element-binding proteins (SREBPs) are
members of the basic helix-loop-helix-leucine zipper (bHLH-
LZ) family of transcription factors and activate transcription
of genes involved in the metabolism of cholesterol, fatty
acids, triglycerides and phospholipids.2 SREBP-1a and -1c
isoforms, both encoded by SREBF-1, but generated by
alternative promoter usage, are more closely related to the
regulation of fatty-acid biosynthesis, whereas the SREBP-2
isoform, encoded by SREBF-2, is preferentially involved in
the regulation of cholesterol homeostasis.2 SREBP-1c is the
predominant isoform in many human tissues, including
liver, skeletal muscle and adipose tissue. Glucose-stimulated
hepatic GLUT2 gene expression as well as insulin effects on
hepatic gene expression are mediated by SREBP-1c.3,4
Hepatic SREBP-1c expression is regulated by nutritional
stimuli like glucose, cyclic adenosine monophosphate and
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polyunsaturated fatty acids.2 Insulin also upregulates skeletal
muscle SREBP-1c gene expression thereby increasing the
expression of glycolytic and lipogenic enzyme genes.5 In
pancreatic b-cells, overexpression of SREBP-1c is associated
with accumulation of triglycerides and impairs insulin
secretion at least in part via upregulation of uncoupling
protein 2.6
SREBF-1 expression has been shown to be reduced in
obesity and T2DM in humans.7,8 A meta-analysis of genome-
wide scans in four European populations showed linkage
between the 17p11 region, comprising SREBF-1, and type 2
diabetes.9 Meanwhile, associations of an exon 18c single-
nucleotide polymorphism (SNP) (rs2297508) within SREBF-1
with obesity and T2DM in French obese and diabetic cohorts
10 and of an intron 18c SNP with T2DM in a British
population sample have been reported.11 Considering
T2DM risk, rs2297508 was the most significantly associated
SNP among 12 variant sites in the transcribed region of
SREBF-1 analyzed in the French study. Owing to the high
linkage disequilibrium (pairwise D040.9, r2¼0.88, Po0.001;
www.hapmap.org) observed between the two variant sites
in exon 18c and intron 18c, we focused on SNP rs2297508
and aimed to confirm the association of this sequence
variation in the transcribed region of SREBF-1 with T2DM
in a well-characterized Austrian population sample. To gain
some mechanistic insight into the relationship of SREBF-1
with T2DM, we also explored possible associations of
rs2297508 with diabetes-related traits, including b-cell




We studied 446 unrelated patients with type 2 diabetes
recruited from the diabetes outpatient clinics of the Land-
eskliniken Salzburg and the Krankenhaus Hallein and 1524
glucose tolerant participants of the Salzburg Atherosclerosis
Prevention Program in Subjects at High Individual Risk
(SAPHIR) study. Inclusion criteria and laboratory parameters
were described elsewhere.12 Associations of genotypes with
estimates of glucose metabolism were determined in 359
glucose tolerant SAPHIR participants, who underwent an
oral glucose tolerance test (OGTT).12 After a 12h overnight
fast, subjects ingested a solution containing 75 g glucose,
and plasma samples were obtained at 0, 30, 60 and 120min
for determination of glucose and insulin. Insulin sensitivity/
resistance was estimated using the homeostasis model
assessment (HOMA) insulin resistance index (HOMAIR), the
composite insulin sensitivity index (Si(comp)), and the meta-
bolic clearance rate (MCR) and Si proposed by Stumvoll et al.
as described.10 b-cell function was estimated by the HOMA-
based insulin release index (HOMASecr), first-phase and
second-phase insulin release and the CIR30 (corrected insulin
response at 30min) as described.12 All study subjects
provided informed consent, and the study was approved by
the local ethics committee. The population comprised only
white Europeans, mainly of Bavarian and Austrian German
descent. Body mass index (BMI) was calculated from
measurements of weight and height. Diabetes was diagnosed
by fasting plasma glucose concentrations of X7.0mmol/l
and/or use of hypoglycemic medications.
Laboratory analyses
Venous blood was collected after an overnight fast. Adipo-
nectin was measured using a human adiponectin ELISA kit
(BioCat GmbH). Plasma glucose, insulin, cholesterol, trigly-
ceride, high-density lipoprotein (HDL) cholesterol and
HbA1c levels were measured as described.10 Genotyping of
rs2297508 was performed using restriction fragment length
polymorphism (RFLP) detection. 50-TCCTGTGCTACTTTGC
CTTTT-30 and 50-GGACAGAGCTGGGAGGTG-30 were used
as forward and reverse primers, respectively, to generate a
370 bp SREBP-1c amplicon harboring the rs2297508 poly-
morphism (GenBank accession number NM_001005291).
Optimum polymerase chain reaction (PCR) conditions were
achieved with 200 mM dG/dA/dT/dCTP, 1.5mM MgCl2 and
0.2U AmpliTaq Gold (Applied Biosystems, Foster City, CA,
USA). Primer concentrations were 200 mM each. PCR products
were digested with XmnI (New England Biolabs, Beverly, MA,
USA) overnight at 371C before separation of fragments in
agarose gels. The accuracy of the RFLP-Assay was verified
by dye-terminator sequencing of the respective DNA region
in 25 DNA samples. The concordance of 150 RFLP – tested
samples performed in duplicate was 100% and all of the
subjects enrolled in our study were successfully genotyped.
Statistics
Differences of continuous variables between type 2 diabetic
men and women and glucose-tolerant controls as well as
effects of genotypes on clinical parameters were ascertained
by two-way analysis of variance (ANOVA). Logarithmic
transformations were made if the equal variance and
normality assumptions of ANOVA were rejected. Measure-
ments were adjusted for effects of age, sex and BMI as
indicated. Allele frequencies were estimated by gene count-
ing. Agreement with Hardy–Weinberg expectations was
tested using a w2 goodness-of-fit test. Differences in genotype
frequencies between subjects with T2DM and controls were
determined using a w2 distribution with two degrees of
freedom. To estimate odds ratios (OR) with confidence
intervals (95% CI) for each genotype, two ‘dummy’ variables
with the respective wild type as the reference were used in
univariate logistic regression analysis. Adjustments for the
study subjects’ age, sex and BMI were made by including
these covariates in a second set of multivariate logistic
regression models. To estimate associations of adiponectin
plasma levels with indices of insulin resistance and b-cell
function, linear models adjusted for age, sex and BMI
were used.
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Results
Our population-based case–control study included 446
T2DM patients (age of T2DM onset o63 years) and 1524
glucose tolerant SAPHIR participants. Average values for
age and BMI were higher and HDL-cholesterol levels were
lower in T2DM patients compared to controls (Table 1). As
expected from the selection criteria, T2DM patients dis-
played higher average values for HbA1c. Gender-specific
differences were observed for age, BMI cholesterol and HDL
cholesterol and a significant interaction between T2DM and
gender was observed for BMI.
Genotype frequencies of SNP rs2297508 observed in our
control group were similar to values reported in a French
population.10 Hardy–Weinberg expectations were fulfilled
in cases and controls. Genotype distributions for SNP
rs2297508 differed between subjects with T2DM and con-
trols (Po0.005). Estimated unadjusted or adjusted diabetes
risks associated with C/G and G/G genotypes were similar,
consistent with a dominant effect of the G allele (Table 2).
Thus, the C/G and the G/G genotype were associated with a
B1.4-fold higher T2DM risk in our study subjects (Table 2).
Gender-specific analysis showed differences of genotype
distributions in male subjects (Po0.0158), but did not reach
significance in female subjects. However, no significant
interaction of genotypes and gender was observed, and
average age and BMI adjusted OR of C/G (C/G 1.40 (0.98–
2.00) vs 1.37 (0.89–2.11); OR (95% CI) male subjects vs
female subjects) and G/G subjects (1.43 (0.86–2.37) vs 1.48
[0.83–2.63]) were similar. In the glucose tolerant subgroup
who underwent OGTT, no associations of genotypes were
observed with indices of insulin resistance and parameters
reflecting the insulin secretory response to glucose. Border-
line genotype-specific associations with HDL-cholesterol
levels were observed in our cross-sectional, non-diabetic
cohort, whereas triglycerides, total cholesterol, low-density
lipoprotein-cholesterol as well as ApoA1 and ApoB levels
were not modified by rs2297508 genotype (Table 3). In the
cross-sectional population, 66 out of 1524 subjects received
lipid-lowering medication. Genotype distributions did not
differ in subgroups with or without drug treatment (data not
shown).
In the control population, plasma levels of adiponectin
were higher in women than in men and showed an inverse
correlation with BMI. Adiponectin levels, adjusted for age,
sex and BMI, showed associations with rs2297508 genotype
distributions (P¼0.0017) (Table 4). In the OGTT control
group, adiponectin levels were associated with indices
of insulin sensitivity/resistance (Si(comp), Po0.001, MCR,
Po0.003; ISI, Po0.002), but not with surrogate markers of
b-cell function.
Discussion
A role of SREBP-1c in T2DM has been suggested from
numerous animal and cell culture models as well as human
studies. Our results confirm associations of an exon 18c SNP
(rs2297508) with T2DM reported previously in a French
diabetic cohort. These studies strongly implicated rs2297508
as a candidate discriminatory site.10 However, data from the
HapMap project (www.hapmap.org) strongly argue for the
Table 1 Clinical characteristics of the study population
Trait Diabetic Non-diabetic P disease P sex P interact
Sex (F/M) 189/257 557/967 F F F
Age (years) 61.1710.6/57.379.7 56.074.3/49.075.4 0.000 (0.000) (0.000)
Diabetes age at onset (years) 49.079.8/49.179.0 F F F F
BMIa (kg/m2) 30.476.0/28.974.9 26.474.6/26.673.7 0.000 0.009 0.0004
Total cholesterolb (mmol/l) 5.3371.51/5.3171.15 6.0571.03/5.9071.0 NS 0.0000 NS
HDLb (mmol/l) 1.4670.46/1.2670.46 1.6670.41/1.3870.33 0.000 0.000 NS
HbA1-c
c (%) 8.271.8/8.271.9 5.470.4/5.370.4 0.000 NS NS
Abbreviations: BMI, body mass index; F, female; HDL, high-density lipoprotein; M, male; NS, not significant. Data are means7s.d. aAdjusted for age. bAdjusted for
age, BMI and lipid lowering drugs. cAdjusted for age and BMI.
Table 2 rs2297508 genotype and associated risk of type 2 diabetes
Without type 2 diabetes With type 2 diabetes P-value OR (95% CI)
N % % N Univariate analysis Multivariate analysis
Genotype
CC 616 40.4 31.8 142 1.00 1.00
CG 697 45.7 51.8 231 1.44 (1.14–1.82) 1.37 (1.04–1.81)
GG 211 13.9 16.4 73 0.0045 1.50 (1.09–2.07) 1.45 (0.99–2.11)
Abbreviations: BMI, body mass index; CI, confidence intervals; OR, odds ratios. P-values, w2 analysis; OR, logistic regression analysis. Multivariate analyses were
adjusted for age, sex and BMI.
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existence of a single haplotype block encompassing the
entire SREBF-1 gene including its promoter. Thus, even
though rs2297508 might affect mRNA structure and meta-
bolism, additional SNPs within the SREBF-1 gene promoter,
not ascertained yet, might be causative sites by affecting
SREBF-1 gene expression. Interestingly, in mice, a functional
variation in the 50 regulatory region of the SREBP-1c gene
influenced promoter activity and was shown to be associated
with defects in fructose- and insulin-induced hepatic
lipogenesis.13
In contrast to a previous case–control study including
morbidly obese French subjects,10 no association was
observed with BMI in our populations that included slightly
overweight subjects only. Furthermore, although previous
studies in different obese and other high-cardiovascular risk
populations reported associations of rs2297508 with an
atherogenic lipid profile,10,14 we only observed a borderline
significant association with HDL-cholesterol levels in our
cross-sectional population. This discrepancies may relate to
differences in population structure. In a more exploratory
approach, we studied possible associations of rs2297508
with diabetes-related traits. Our studies in glucose tolerant
subjects failed to identify associations of rs2297508 with
indices of insulin sensitivity or b-cell function. Similar results
have been reported for the intron 19c SNP that was
associated with T2DM in a British population.11
However, the association of rs2297508 with plasma
adiponectin levels observed in our non-diabetic cohort
suggests a potential mechanism that may contribute to the
role of the SREBP-1 variants in T2DM. Adiponectin is an
adipose-derived plasma protein that is encoded by ACRP30/
ACDC and hypoadiponectinemia was observed in patients
with obesity, insulin resistance and type 2 diabetes.15 SREBP-
1c has been shown to regulate adiponectin gene expression
in differentiated mouse adipocytes.16 Although the human
and rodent adiponectin gene promoter reveal only a
moderate degree of homology, several putative binding sites
for SREBPs are present in the human gene promoter (data
not shown). Moreover, SREBP-1c mRNA expression is down-
regulated in the intra- and extraperitoneal adipose tissue of
obese humans, but is restored upon weight loss.7 Similarly,
circulating adiponectin is decreased in obesity,17 whereas
weight reduction results in increased plasma adipo-
nectin.18,19 Several studies showed associations of circulating
adiponectin levels with insulin sensitivity,15 a result, that
was also observed in our control group.
It is thus conceivable that effects on adiponectin gene
expression may play a role in the association of the SREBF-1
locus with T2DM. However, our preliminary results obtained
from a cross-sectional population sample should be inter-
preted with caution and will require confirmation in larger
populations.
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